跳至主要内容
临床试验/NCT03014180
NCT03014180已完成不适用

Clinical Evaluation of LEft VEntricular Auto Threshold Algorithm

LivaNova1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年2月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
LivaNova
入组人数
60
试验地点
1
主要终点
Percentage of Successful"In-Clinic LVAT" Test

研究概览

简要总结

The purpose of the LEVEA study is to assess the performances of a new automatic left ventricular auto threshold (LVAT) algorithm (In-Clinic LVAT algorithm) when used by physicians during in-hospital follow-up.

详细描述

"In-Clinic LVAT" feature is a non CE-marked feature designed to be activated by the physician during 2 hospital follow-ups:

  • first visit: planned to be conducted 15 days maximum after inclusion
  • second visit: planned to be conducted between 1 and 3 months after the first visit The evaluation consists in the comparison between the threshold value provided by the algorithm and the threshold value obtained manually by the physician.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Subject already implanted (de-novo, upgrade or replacement) according to the relevant ESC Guidelines [1]:
  • •With IS1 Platinium SonR CRT-D (models 1811, 1841, CE-marked) for maximum of 5 days or;
  • •With IS4 Platinium SonR CRT-D (model 1844, CE-marked).
  • •Right atrial, right and left ventricular leads must be implanted. Only bipolar and quadripolar for Left Ventricular lead.
  • •Reviewed, signed and dated informed consent.

排除标准

  • •Subject included in another clinical study that could confound the results of this study;
  • •Malfunction or dislodgment of right atrial, right and left ventricular implanted leads;
  • •Subject diagnosed with permanent atrial fibrillation;
  • •Known pregnancy;
  • •Minor age;
  • •Under protection or guardianship;
  • •Unavailability for scheduled follow-up or refusal to cooperate

研究组 & 干预措施

"In-Clinic LVAT"

Experimental

All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.

干预措施: "In-Clinic LVAT" (Device)

结局指标

主要结局

Percentage of Successful"In-Clinic LVAT" Test

时间窗: 0-3 months post inclusion

The success rate is defined as the equivalence between the value measured by the algorithm and the measure obtained manually by the physician on 5 identified pacing vectors during the visit among at least 231 LV tests.

次要结局

  • Percentage of Accurate "In-Clinic LVAT" Test Assessed by an Independent Reviewer(0-15 days post inclusion)
  • Percentage of Successful "In-Clinic LVAT" Test at M1 Visit(1-3 months after first visit)
  • Percentage of Successful of "In-Clinic LVAT" Test at M0 Visit(0-15 days post inclusion)
  • Percentage of Eligible Subjects to LVAT Feature(0-3 months post inclusion)
  • Safety of the LVAT Algorithm(0-3 months post inclusion)

研究者

发起方
LivaNova
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验